A surge in drug good manufacturing practices warning letters to active pharmaceutical ingredient suppliers last year could spell trouble for the pharmaceutical industry.
The jump in warnings to API suppliers helped drive last year’s total for drug GMP warning letters to
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?